Physicians consider adopting intravitreal bevacizumab as routine treatment for ROP

May 2011
Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p1
Academic Journal
The article discusses a debate among U.S. physicians regarding the potential adoption of intravitreal bevacizumab as retinopathy of prematurity (ROP) treatment in 2011.


Related Articles

  • Anti-VEGF therapy superior to laser for preventing recurrences of retinopathy of prematurity. KUZNAR, WAYNE // Contemporary Pediatrics;Mar2011, Vol. 28 Issue 3, p14 

    No abstract available.

  • Round table: Are physicians ready to adopt intravitreal bevacizumab as routine treatment for ROP?  // Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p32 

    An excerpt from a round table discussion conducted at the 2011 American Association for Pediatric Ophthalmology and Stabismus (AAPOS) which focused on the efficacy of intravitreal bevacizumab in treating retinopathy is presented.

  • Anti-VEGF treatment for acute ROP - not yet recommended! Gilbert, Clare // Community Eye Health Journal;2014, Vol. 27 Issue 87, p46 

    The author cites several reasons why anti-vascular endothelial growth factor (VEGF) drugs are not recommended for severe retinopathy of prematurity (ROP) including the effectiveness in preventing early recurrence and major concerns about the short and long-term impact of anti-VEGF on babies.

  • Intravitreal anti-VEGF yields significant benefit in treatment of stage 3+ ROP. Hasson, Matt // Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p30 

    The article discusses research on the effect of intravitreal bevacizumab treatment on patients with stage 3 acute retinopathy of prematurity, published in the 2011 issue of the "New England Journal of Medicine."

  • Retinopathy of Prematurity and Scientific Investigation. Wagner, Rudolph S. // Journal of Pediatric Ophthalmology & Strabismus;Jan/Feb2012, Vol. 49 Issue 1, p9 

    An introduction is presented in which the editor discusses various reports within the issue on topics including plus disease, retinopathy of prematurity (ROP) and grant funding for pediatric ophthalmology.

  • Retinopathy of prematurity: are we screening too many babies? Matthew, M.R.K.; Fern, A.I.; Hill, R. // Eye;Sep2002, Vol. 16 Issue 5, p538 

    Ascertains the incidence and associated risk factors that may contribute to the management of babies with retinopathy of prematurity (ROP) in the Landshire District, Scotland. Birth weight; Gestational age; ROP incidence; Frequency of babies born with ROP.

  • Telemedicine initiative identified treatable cases of retinopathy of prematurity. Bechtel, Bryan; Hasson, Matt // Ocular Surgery News Europe;Apr2010, Vol. 21 Issue 4, p28 

    The article discusses the findings of a study which revealed that the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) telemedicine initiative had identified all treatable cases of retinopathy of prematurity.

  • Retinopathy of prematurity. Donahue, S.P. // British Journal of Ophthalmology;Oct2002, Vol. 86 Issue 10, p1071 

    Editorial. Focuses on the factors which influenced the incidence and severity of retinopathy of prematurity (ROP). Effects of advances in neonatal care on the incidence and severity of ROP; Shift in the distribution of ROP; Need to focus screening efforts to target those most at risk of ROP.

  • Reply to 'Change in subfoveal choroidal thickness in central serous chorioretinopathy'. Kim, Y T // Eye;Oct2013, Vol. 27 Issue 10, p1222 

    A response from the author of the article "Change in Subfoveal Choroidal Thickness in Central Serous Chorioretinopathy," published in previous issue of the journal is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics